[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"clonal-cytopenia-of-undetermined-significance\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:clonal-cytopenia-of-undetermined-significance":40},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,12,0,[8,63,91,116,141,164,193,222,247,272,292,321],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":41,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":51,"lastUpdatePostDateStruct":52,"startDateStruct":55,"completionDateStruct":57,"leadSponsor":59,"locationsCount":62},"100644985","clonal-hematopoiesis-chemotherapy-and-radiation-effects-study-100644985",false,"NCT07675967","Clonal Hematopoiesis Chemotherapy and Radiation Effects Study","CH CARE","Inclusion Criteria:\n\n* Participants to be included in this study include the following:\n* Adults age \\>18 years\n* Diagnosed with solid malignancy (breast, ovarian, lung, gastric, colorectal, esophageal, uterine, head and neck, or sarcoma cancers)\n* Have a pending plan to receive chemotherapy or radiation for their solid malignancy (cancer).\n* Has not received cytotoxic chemotherapy or radiation for their solid cancer diagnosis in the past.\n\nExclusion Criteria:\n\n* Individuals without plans for cytotoxic chemotherapy, radiation or PARP inhibitor exposure\n* Individuals who have received prior chemotherapy and or radiation for their current solid malignancy (cancer)\n* Individuals with any prior history of blood cancer (leukemia, myelodysplastic syndrome, lymphoma, multiple myeloma, including smoldering multiple myeloma). Persons with blood cancer precursors including clonal hematopoiesis of indeterminate potential (CHIP), clonal cytopenia of uncertain significance (CCUS), monoclonal B lymphocytosis (MBL), monoclonal gammopathy of uncertain significance (MGUS) are eligible for study participation.","ALL","18 Years",{"count":19,"type":20},5000,"ESTIMATED","OBSERVATIONAL","The goal of the Clonal Hematopoiesis Chemotherapy and Radiation Effects (CH CARE) Study is to understand how the presence or absence of clonal hematopoiesis (CH) influences outcomes in people receiving chemotherapy and radiation for solid cancers.\n\nThe study will collect biospecimens and clinical information. These data will be used to define clinical and molecular features that predict the presence of high-risk clonal hematopoiesis (CH) in patients exposed to cytotoxic anti-cancer therapy. Predictive features will be utilized to identify populations of cancer patients and survivors who are at the highest risk of developing therapy-related myeloid neoplasms (t-MNs).\n\nUltimately this study will result in the development of a novel novel risk prediction algorithm for t-MNs in patients with solid cancers and drive potential therapeutic approaches to intercept progression from CH to often fatal t-MNs.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40],"Lung Cancer (Diagnosis)","Osteochondroma","Spitz Nevus","Solid Cancers","Breast Cancer","Gastric (Stomach) Cancer","Colorectal (Colon or Rectal) Cancer","Sarcoma","Ovarian Adenocarcinoma","Uterine Adenocarcinoma","Endometrial Adenocarcinoma","Esophageal Adenocarcinoma","Head and Neck Cancer","Therapy-Related Acute Myeloid Leukemia","Therapy-Related MDS","Clonal Hematopoiesis of Indeterminate Potential (CHIP)","Clonal Cytopenia of Undetermined Significance",[42,43,44,45,46,47,48,49],"Adult cancer survivors","Precursor Lesions","clonal hematopoiesis","chemotherapy","radiation","therapy-related myeloid neoplasms","CCUS","clonal hematopoiesis of indeterminate potential","RECRUITING","2026-06-29",{"date":53,"type":54},"2026-06-30","ACTUAL",{"date":56,"type":54},"2025-04-04",{"date":58,"type":20},"2035-03-31",{"name":60,"class":61},"Dana-Farber Cancer Institute","OTHER",1,{"id":64,"slug":65,"hasResults":11,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":4,"eligibilityCriteria":69,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":70,"enrollmentInfo":71,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":73,"conditions":74,"keywords":76,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":62},"100370367","chipccus-natural-history-protocol-100370367","NCT04102423","CHIP\u002FCCUS Natural History Protocol","Investigation of the Natural Progression of Clonal Hematopoiesis of Indeterminate Potential and Clonal Cytopenia of Undetermined Significance.","* Participants with Clonal Hematopoiesis of Indeterminate Significance (CHIP):\n\nINCLUSION CRITERIA:\n\n* Greater than or equal to 18 years of age\n* Willingness and capacity to provide written informed consent\n* Presence of a somatic pathogenic variant associated with hematological malignancy\n* Variant allele fraction of greater than or equal to 2% in at least one identified somatic pathogenic variant\n\nEXCLUSION CRITERIA:\n\n* Known diagnosis of a hematological malignancy or bone marrow failure syndrome (excluding MGUS or MBL)\n* Presence of a cytopenia:\n\n  --Hemoglobin, \\\u003C10 g\u002FdL; platelet count, \\\u003C100 X 10\\^9 \u002FL; or absolute neutrophil count, \\\u003C1.5 X 10\\^9 \u002FL\n* Pregnant at the time of recruitment\n\nParticipants with Clonal Cytopenia of Uncertain Significance (CCUS):\n\nINCLUSION CRITERIA:\n\n* Greater than 18 years of age\n* Willingness and capacity to provide written informed consent\n* Presence of a somatic pathogenic variant associated with hematological malignancy without morphological evidence of\n\nmyelodysplasia and without a MDS defining cytogenetic abnormality\n\n* Variant allele fraction of greater than or equal to 2% in at least one identified somatic pathogenic variant\n* Bone marrow aspirate and biopsy excluding hematological malignancy and MDS\n* Presence of a cytopenia for \\>30 days\n\n  * Hemoglobin, \\\u003C10 g\u002FdL; platelet count, \\\u003C100 X10\\^9 \u002FL; or absolute neutrophil count, \\\u003C1.5 X10\\^9 \u002FL\n  * At least 2 CBCs documented in a non-hospitalized patient at least 3 days apart\n\nEXCLUSION CRITERIA:\n\n* Known diagnosis of a hematological malignancy or bone marrow failure syndrome (excluding MGUS or MBL)\n* Morphological evidence of dysplasia on bone marrow aspirate \u002F biopsy 10% dysplastic cells in any hematopoietic lineage\n* Ringed sideroblasts \\>15%\n* Presence of MDS defining cytogenetic abnormality\n\n  * Del(7q)\n  * del(5q)\n  * 17q or t(17p)\n  * Del(13q)\n  * del(11q)\n  * del(12p) or t(12p)\n  * del(9q)\n  * idic(X)(q13)\n  * t(11;16)\n  * t(3;21)\n  * t(1;3)\n  * t(2;11)\n  * inv(3)\u002Ft(3;3)\n* t(6;9)\n\n  --Note: As a sole cytogenetic abnormality in the absence of morphological criteria, gain of chromosome 8, del(20q) and loss of chromosome Y are not considered definitive evidence of MDS.\n* Alternate hematological diagnosis causing cytopenia\n* Pregnant at time of recruitment","99 Years",{"count":72,"type":20},306,"Background:\n\nClonal Hematopoiesis of Indeterminate Potential (CHIP) is a change in a person s DNA that can increase a person s risk of developing blood cancers or cardiovascular disease. CHIP occurs mostly occurs in older people. Clonal cytopenia of undetermined significance (CCUS) occurs when one or more blood cell types is lower than it should be and is associated with a change in their DNA. Researchers want to learn more about how CHIP and CCUS progress.\n\nObjective:\n\nTo examine the natural history of people in a study of CHIP and CCUS to (1) verify the association of myeloid somatic mutations with atherosclerosis and blood cancers, and (2) find new potential clinical associations.\n\nEligibility:\n\nAdults 18 and older with CHIP with a somatic pathogenic variant associated with blood cancers. Adults with CCUS are also needed.\n\nDesign:\n\nPotential participants will be screened with gene testing. For this, they will give a blood sample. They will also be enrolled in NHLBI screening protocol #97-H-0041. Those who pass this screening will visit the NIH Clinical Center for more screening tests. For this, they will give a blood sample. They will have a physical exam. They will give their medical history. They may give a urine sample. Those with CCUS will have bone marrow taken.\n\nEligible participants will give blood and urine samples. Their heart activity will be monitored and tested. The arteries in their neck will be assessed using ultrasound. They will have liver and heart scans. They will have a bone mineral density scan. They will have lung function tests. They will have the inside of their cheek swabbed or have a skin punch biopsy. They will have the option to have advanced scans done of their heart and full body but this is not required.\n\nParticipants will have yearly follow-up visits for 10 years. They will repeat the above procedures every 1-3 years depending on the procedure.",[75,40],"Clonal Hematopoiesis of Indeterminate Potential",[77,78,79,80],"Cytopenia","Myelodysplastic Syndrome","Somatic Mutations","Natural History","2026-06-17",{"date":83,"type":54},"2026-06-18",{"date":85,"type":54},"2020-03-03",{"date":87,"type":20},"2033-09-15",{"name":89,"class":90},"National Heart, Lung, and Blood Institute (NHLBI)","NIH",{"id":92,"slug":93,"hasResults":11,"nctId":94,"briefTitle":95,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":98,"targetDuration":4,"studyType":100,"phases":101,"briefSummary":103,"conditions":104,"keywords":105,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":62},"100638237","phase-2-research-on-nicotinamide-riboside-supplement-support-in-mds-ross-trial-100638237","NCT07579429","Research On Nicotinamide Riboside Supplement Support in MDS (ROSS Trial)","ROSS","Inclusion Criteria:\n\n* Subject must voluntarily sign and date an informed consent, approved by an Institutional Review Board (IRB), prior to the initiation of any research directed procedures.\n* Stated willingness to comply with all study procedures and be available for the duration of the study.\n* Be a male or female aged ≥ 18 years of age.\n* For persons of reproductive potential, use of highly effective method(s) of contraception.\n* Subject must have confirmation of high risk CCUS (defined by CHRS score) or the diagnosis of MDS in the lower risk category as defined by IPSS-M less than 0.\n* Patients must have ECOG of ≤ 2\n* Subject must have adequate renal function as demonstrated by a calculated creatinine clearance ≥ 30 mL\u002Fmin; determined via urine collection for 24-hour creatinine clearance or by the Cockcroft Gault formula.\n* Subject must have adequate liver function as demonstrated by:\n\n  * aspartate aminotransferase (AST) ≤ 3.0 × ULN\n  * alanine aminotransferase (ALT) ≤ 3.0 × ULN\n  * Unless due to Gilbert's syndrome, patients must have a total bilirubin ≤ 3 × ULN.\n* Subject is informed that consumption of the following fruits is prohibited 3 days prior to the initiation of study treatment and throughout participation: grapefruit, grapefruit products, Seville oranges (including marmalade containing Seville oranges) or Star fruit.\n\nExclusion Criteria:\n\n* Subject is known to be positive for HIV with uncontrolled disease. HIV testing is not required.\n* Subject is known to be positive for hepatitis B or C infection with the exception of those with an undetectable viral load. Hepatitis B or C testing is not required and subjects with serologic evidence of prior vaccination to HBV may participate.\n* Subject has any history of clinically significant condition(s) that in the opinion of the investigator would adversely affect his\u002Fher participating in this study including, but not limited to:\n\n  * Significant active cardiac disease within the previous 6 months including: New York Heart Association heart failure \\> class 2, unstable angina, or myocardial infarction.\n  * Renal, neurologic, psychiatric, endocrinologic, metabolic, immunologic, hepatic, cardiovascular disease, or bleeding disorder independent of leukemia.\n* Subject has a malabsorption syndrome or other condition that precludes enteral route of administration. This includes history of inflammatory bowel disease (e.g. Crohn's disease, ulcerative colitis), celiac disease (e.g. sprue), prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with the absorption, distribution, metabolism or excretion of the study drug and\u002For predispose the subject to an increased risk of gastrointestinal toxicity.\n* Subject exhibits evidence of uncontrolled systemic infection requiring therapy (viral, bacterial or fungal). Uncontrolled is defined as ongoing signs\u002Fsymptoms related the infection without improvement despite appropriate antibiotics, antiviral therapy and\u002For other treatment.\n* Subject has a history of other malignancies prior to study entry, with the exception of:\n\n  * Adequately treated in situ carcinoma of the breast or cervix uteri\n  * Basal cell carcinoma of the skin or localized squamous cell carcinoma of the skin\n  * Prostate cancer not requiring therapy beyond hormonal therapy\n  * Previous malignancy confined and surgically resected (or treated with other modalities) with curative intent\n* Any subject who is transfusion dependent and a candidate for MDS therapy such as erythroid stimulating agents, thrombopoietin receptor agonists, Lusparercept, Imetelstat or hypomethylating agents.\n* Pregnant or breast-feeding females. A pregnancy test will be obtained at the time of screening if applicable.\n* Known or suspected hypersensitivity to nicotinamide riboside and pterostilbene.",{"count":99,"type":20},10,"INTERVENTIONAL",[102],"PHASE2","This is an open-label, phase 2 study for lower risk MDS and high risk CCUS patients who are transfusion independent. There will be two cohorts enrolled at the same time to measure the effect of nicotinamide riboside and pterostilbene at different doses. The primary goals of the study are:\n\n* to assess if study drug improves cytopenias in patients\n* to determine safety of the study drug in patients",[40,78],[106],"Lower Risk Myelodysplastic Syndromes","2026-06-01",{"date":109,"type":54},"2026-06-03",{"date":111,"type":54},"2026-05-20",{"date":113,"type":20},"2030-12-18",{"name":115,"class":61},"University of Colorado, Denver",{"id":117,"slug":118,"hasResults":11,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":4,"eligibilityCriteria":122,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":100,"phases":125,"briefSummary":126,"conditions":127,"keywords":129,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":62},"100534586","phase-2-enasidenib-for-patients-with-clonal-cytopenia-of-undetermined-significance-and-mutations-in-idh2a-decentralized-trial-100534586","NCT06240754","Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2A Decentralized Trial","A Pilot Study of Enasidenib for Patients With Clonal Cytopenia of Undetermined Significance and Mutations in IDH2: A Decentralized Trial","Inclusion Criteria:\n\n* Unexplained cytopenia for at least 6 months. Cytopenia is defined as the presence of ≥1 blood count indexes below the following thresholds:\n\n  * Hgb \\\u003C10 g\u002FdL\n  * ANC \\\u003C1.8 × 109\u002FL\n  * Platelets \\\u003C100 × 109\u002FL\n* IDH2 gene mutation (R140 or R172), performed locally, at a frequency ≥ 2%.\n* At least 18 years of age.\n* ECOG performance status 0-2\n* Adequate organ function as defined below:\n\n  * AST(SGOT)\u002FALT(SGPT) ≤ 3.0 x IULN\n  * Serum total bilirubin \\\u003C 1.5 x IULN (un upper limit of bilirubin 5 mg\u002FdL is acceptable if it can be attributed to Gilbert's syndrome or erythropoiesis)\n  * Creatinine clearance \\> 50 mL\u002Fmin by Cockcroft-Gault glomerular filtration rate estimation or serum creatinine ≤ 2 x IULN\n* The effects of enasidenib on the developing human fetus are unknown. For this reason, women of childbearing potential and men must agree to use adequate contraception prior to study entry, for the duration of study participation, and for 24 months after the last dose of enasidenib. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and for 4 months after the last dose of enasidenib.\n* Ability to understand and willingness to sign an IRB approved written informed consent document. Legally authorized representatives may sign and give informed consent on behalf of study participants.\n\nExclusion Criteria:\n\n* Indication of hematologic disease by bone marrow biopsy within 6 months of study entry.\n\n  * Evidence of disease progression from time of bone marrow biopsy to enrollment based on investigator review of symptoms and complete blood counts\n* Active malignancy (defined as \\> 1 cm disease on most recent CT scan in the past 6 months).\n* Currently receiving therapy for solid tumor malignancy or received within the last 6 months.\n* Currently receiving any other investigational agents.\n* Known dysphagia, short-gut syndrome, gastroparesis, or other conditions that limit the ingestion or gastrointestinal absorption of drugs administered orally.\n* A history of allergic reactions attributed to compounds of similar chemical or biologic composition to enasidenib or other agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative pregnancy test within 72 hours of study entry.\n* Positive direct Coombs test.",{"count":124,"type":20},15,[102],"Study researchers think that a drug called enasidenib may help people with clonal cytopenia of undetermined significance (CCUS) because the drug blocks the mutated IDH2 protein, which may improve blood cell counts. The purpose of this study is to find out whether enasidenib is a safe and effective treatment for CCUS.",[40,128],"CCUS Clonal Cytopenia of Undetermined Significance",[40,48,130,131],"IDH2","Enasidenib","2026-05-22",{"date":134,"type":54},"2026-05-27",{"date":136,"type":54},"2024-10-10",{"date":138,"type":20},"2029-02-28",{"name":140,"class":61},"Washington University School of Medicine",{"id":142,"slug":143,"hasResults":11,"nctId":144,"briefTitle":145,"officialTitle":146,"acronym":4,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":148,"targetDuration":4,"studyType":100,"phases":150,"briefSummary":152,"conditions":153,"keywords":154,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":155,"lastUpdatePostDateStruct":156,"startDateStruct":158,"completionDateStruct":160,"leadSponsor":162,"locationsCount":62},"100577734","early-phase-1-early-intervention-in-high-risk-ccus-100577734","NCT06802146","Early Intervention in High Risk CCUS","A Multi-Site Break Through Cancer Pilot Study Testing the Feasibility and Safety of Therapeutic Intervention for Patients With High-risk Clonal Cytopenia of Undetermined Significance (CCUS)","Inclusion Criteria:\n\n* Age ≥18 years.\n* Unexplained cytopenia(s) for at least 4 months (at least two separate labs within 4 months including at time of screening must meet this criteria). Cytopenia(s) defined as the presence of ≥ 1 of the following:\n\n  * Hemoglobin (Hgb) \\\u003C12 g\u002FdL for women and \\\u003C13g\u002FdL for men\n  * Absolute neutrophil count (ANC) \\\u003C 1.8 × 109\u002FL\\*\n  * Platelet count (Plt) \\\u003C150 × 109\u002FL \\*Patients known to have a Duffy-null genotype must have anemia (Hgb \\\u003C 12g\u002FdL for women, Hgb \\\u003C13g\u002FdL for men) and\u002For thrombocytopenia (Plt \\\u003C 150 × 109\u002FL) to be eligible for this study.\n\n    * 1 pathogenic variant detected in any myeloid driver gene with a VAF of at least 0.02 (2%) identified by local next generation sequencing (NGS) of peripheral blood or bone marrow sample within 3 months from screening bone marrow biopsy.\n* Participants must have a high risk score per the Clonal Hematopoiesis Risk Calculator (CHRS). See APPENDIX C for calculation.\n* Screening bone marrow biopsy must not be diagnostic of any overt hematologic malignancy by morphologic assessment and must be consistent with a diagnosis of clonal cytopenia of unknown significance (CCUS) as determined by multi-institutional hematopathology review.\n* ECOG performance status 0-2 (see Appendix A).\n* Participants must meet the following organ function as defined below:\n\n  * Serum aspartate aminotransferase\u002Fserum glutamic oxaloacetic transaminase (AST\u002FSGOT) and alanine aminotransferase (ALT\u002FSGPT) ≤3x upper limit of normal (ULN).\n  * Serum total bilirubin \\\u003C1.5x ULN. Higher levels are acceptable if these can be attributed to ineffective erythropoiesis or Gilbert's syndrome. In these cases, approval from the study Sponsor-Investigator is required.\n  * Creatinine clearance greater than 40 mL\u002Fmin based on the Cockcroft-Gault glomerular filtration rate estimation.\n* Ability to understand and the willingness to sign a written informed consent document.\n* For participants of the early pharmacologic intervention cohort: women of childbearing potential must use highly effective contraception during treatment for at least 6 months after the last dose and males with female partners of reproductive potential should use effective contraception during treatment and for 3 months after the last dose.\n\nExclusion Criteria:\n\n* Concurrent primary malignancy requiring active cytotoxic chemotherapy and\u002For ionizing radiation therapy.\n* Known inherited bone marrow failure disorder and\u002For germline predisposition to hematologic malignancy.\n* Receipt of anti-cancer therapy including any cytotoxic chemotherapy, ionizing radiation therapy, immunomodulatory agents such as lenalidomide, and targeted anti-cancer therapies including PARP inhibitors within the last 6 months. Patients with complete surgical resection of a tumor are not excluded from this study.\n* Anti-cancer therapy, including any cytotoxic chemotherapy, ionizing radiation therapy, immunomodulatory agents such as lenalidomide and targeted agents such as PARP inhibitors, planned in the next 6 months. Patients on hormonal adjuvant therapy for nonmetastatic breast and prostate cancer or other minimally-myelosuppressive maintenance therapies for non-metastatic cancer may be eligible at the discretion of the study PI.\n* Diagnosis of MDS, MPN, CMML, AML or any other hematolymphoid malignancy in the patient's lifetime. This includes individuals with MDS-defining chromosomal abnormalities identified via conventional karyotype or FISH.\n* Presence of a concurrent hematologic malignancy precursor state, such as smoldering multiple myeloma (SMM), and smoldering Waldenstrom's macroglobulinemia.\n* Presence of an early-stage hematologic precursor state-such as monoclonal gammopathy of undetermined significance (MGUS) and monoclonal B cell lymphocytosis (MBL).\n* Active uncontrolled systemic fungal, bacterial, or viral infection (defined as ongoing signs\u002Fsymptoms related to the infection without improvement despite appropriate antibiotics, antiviral therapy, and\u002For other treatment).\n* Recent (within 3 months) vaccination with any live attenuated vaccine or vaccination with live attenuated vaccine planned during the next 15 months. \\*Live attenuated vaccines include measles, mumps, rubella (MMR combined vaccine), rotavirus, smallpox, chickenpox, and yellow fever.\n* Laboratory evidence indicative of clinically significant red cell hemolysis.\n* Hypersplenism and\u002For evidence of portal hypertension on physical exam or imaging.\n* Pregnant or lactating.",{"count":149,"type":20},108,[151],"EARLY_PHASE1","This research is being done to find out more about the potential risks and benefits of early treatment in participants with high risk Clonal Cytopenia of Unknown Significance (CCUS). This study will give eligible CCUS participants the option of either being observed or taking an oral drug as treatment.\n\nThe names of the study drug involved in this study is:\n\n-Decitabine\u002Fcedazuridine (DEC\u002FCED) (a nucleoside metabolic inhibitor and cytidine deaminase inhibitor).",[40,77],[40,48,77],"2026-04-20",{"date":157,"type":54},"2026-04-23",{"date":159,"type":54},"2025-02-07",{"date":161,"type":20},"2028-12-01",{"name":163,"class":61},"Lachelle D. Weeks, MD, PhD",{"id":165,"slug":166,"hasResults":11,"nctId":167,"briefTitle":168,"officialTitle":169,"acronym":4,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":187,"completionDateStruct":189,"leadSponsor":191,"locationsCount":62},"100538832","clonal-hematopoiesis-and-therapy-emergent-myeloid-neoplasms-in-patients-with-cancers-chances-study-100538832","NCT06295965","Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study","Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers (CHANCES)","Inclusion Criteria:\n\n* Subjects who have or have had ovarian, peritoneal, or fallopian tube carcinoma who have a life expectancy of greater than 6 months and:\n\n  * Have completed or plan to complete at least 5 cycles of platinum-based chemotherapy\n\nOR\n\n* Subjects who have or have had a solid tumor diagnosis and any of the following:\n\n  * At least 4 months of exposure to a PARP inhibitor\n  * Diagnosis of a blood disorder including, but not limited to, clonal hematopoiesis of indeterminate potential, cytopenia of unknown significance, or therapy-related myeloid neoplasm\n\nExclusion Criteria:\n\n* Individuals with a life expectancy of less than 6 months",{"count":172,"type":20},2000,"This study is being done to investigate clonal hematopoiesis and therapy-emergent myeloid neoplasms in patients with ovarian or other solid cancers. Researchers want to identify risk factors for developing these blood cancers as well as if there is\u002Fare a genetic\u002Fenvironmental component(s) to developing blood cancer.",[175,176,177,178,40,179,180,181,182,183],"Recurrent Fallopian Tube Carcinoma","Recurrent Ovarian Carcinoma","Recurrent Primary Peritoneal Carcinoma","Recurrent Malignant Solid Neoplasm","Clonal Hematopoiesis","Idiopathic Cytopenia of Undetermined Significance","Non-Neoplastic Hematopoietic and Lymphoid Cell Disorder","Ovarian Carcinoma","Myeloid Neoplasm Post Cytotoxic Therapy","2026-04-14",{"date":186,"type":54},"2026-04-17",{"date":188,"type":54},"2024-01-02",{"date":190,"type":20},"2031-12-31",{"name":192,"class":61},"University of Washington",{"id":194,"slug":195,"hasResults":11,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":100,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":212,"lastUpdatePostDateStruct":213,"startDateStruct":215,"completionDateStruct":217,"leadSponsor":219,"locationsCount":221},"100317852","phase-2-ascorbic-acid-and-chemotherapy-for-the-treatment-of-relapsed-or-refractory-lymphoma-ccus-and-chronic-myelomonocytic-leukemia-100317852","NCT03418038","Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia","Phase2 Trial of High Dose Intravenous Ascorbic Acid as an Adjunct to Salvage Chemotherapy in Relapsed\u002F Refractory Lymphoma, Patients With Clonal Cytopenia of Undetermined Significance, and Chronic Myelomonocytic Leukemia","Inclusion Criteria:\n\n* Age \\>= 18 years\n* Biopsy-proven relapsed or refractory lymphomas; relapsed is defined as a relapse that occurred after having a response to the last therapy that lasted \\> 6 months; refractory is no response or relapse within 6 months; previous biopsies \\\u003C 6 months prior to treatment on this protocol will be acceptable\n\n  * NOTE: Arms A\u002FB - relapsed or refractory DLBCL within 24 months from the end of anthracycline-based therapy; no prior salvage therapy; patients can have received radiation therapy as part of initial treatment but not specifically for relapse\n  * NOTE: Arm C patients include relapsed or refractory lymphoma patients of any type for which the recommended treatment includes one of the platinum-based regimens; of note, relapsed or refractory double-hit high grade lymphoma patients and relapsed or refractory Hodgkin lymphoma patients will be enrolled in Arm C; there is no limit on the number of prior therapies for Arm C patients; the patient must be eligible for a platinum-based regimen and must not have received the same regimen in the past without responding\n* Measurable or assessable disease: measurable disease is defined as measurable by computed tomography (CT) \\[dedicated CT or the CT portion of a positron emission tomography (PET)\u002FCT\\] or magnetic resonance imaging (MRI): to be considered measurable, there must be at least one lesion that has a single diameter of \\>= 1.5 cm\n\n  * NOTE: Skin lesions can be used if the area is \\>= 1.5 cm in at least one diameter and photographed with a ruler; patients with assessable disease by PET are also eligible as long as the assessable disease is biopsy proven lymphoma\n* Arms A\u002FB - eligible for treatment with ifosfamide, carboplatin, and etoposide (+\u002F- rituximab)\n* Arm C eligible for treatment with one of the following standard, every 3 week, platinum-based salvage regimens (with or without monoclonal antibody as appropriate for the disease):\n\n  * Ifosfamide\u002Fcarboplatin\u002Fetoposide (ICE) or rituximab\u002Fifosfamide\u002Fcarboplatin\u002Fetoposide (RICE);\n  * Cisplatin, cytarabine (cytosine arabinoside), dexamethasone (DHAP) or RDHAP;\n  * Gemcitabine hydrochloride (gemcitabine), dexamethasone, cisplatin (GDP) or rituximab, gemcitabine, dexamethasone, cisplatin (RGDP);\n  * Gemcitabine and oxaliplatin (GemOx) or rituximab, gemcitabine and oxaliplatin (RGemOx);\n  * Oxaliplatin, cytosine arabinoside, dexamethasone (OAD) or rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD)\n* Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0, 1 or 2\n* Hemoglobin \\>= 8.0 g\u002FdL (may transfuse to meet this requirement), obtained =\\\u003C 14 days prior to registration\n* Absolute neutrophil count (ANC) \\>= 1500\u002Fmm\\^3, obtained =\\\u003C 14 days prior to registration\n* Platelet count \\>= 75000\u002Fmm\\^3, obtained =\\\u003C 14 days prior to registration\n* Total bilirubin =\\\u003C 2 x upper limit of normal (ULN) (if \\> 2 x ULN direct bilirubin is required and should be =\\\u003C 1.5 x ULN), obtained =\\\u003C 14 days prior to registration\n* Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\\\u003C 3 x ULN (=\\\u003C 5 x ULN for patients with liver involvement), obtained =\\\u003C 14 days prior to registration\n* Creatinine =\\\u003C 1.6 mg\u002FdL; if over 1.6 then the calculated creatinine clearance must be \\>= 55 ml\u002Fmin using the Cockcroft-Gault formula, obtained =\\\u003C 7 days prior to registration\n* Negative pregnancy test done =\\\u003C 7 days prior to registration, for persons of childbearing potential only\n\n  * NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* Human immunodeficiency virus (HIV) test done =\\\u003C 14 days prior to registration\n\n  * If positive, the CD4 count must be \\> 400\n* Provide written informed consent\n* Willingness to have a central venous line \\[peripherally inserted central catheter (PICC) or PORT\\]\n* Willingness to provide mandatory blood specimens for correlative research\n* Willingness to provide mandatory tissue specimens for correlative research\n* Willingness to return to enrolling institution for follow-up (during the active monitoring phase of the study)\n* Willingness to follow the requirements of the intravenous ascorbic acid program schedule\n* ARM D: Patients who had a diagnosis of CCUS with one or more TET2 mutations or TET2 mutations with concurrent splicing genes mutations (SRSF2, U2AF1, SF3B1, and ZRSR2) or epigenetic regulator mutations (DNMT3A, EZH2, IDH1, IDH2). CCUS diagnosis being defined based on the absence of definitive morphologic evidence of hematologic neoplasms from bone marrow biopsy evaluation combined with evidence of pathogenic myeloid somatic mutation with a variant allele frequency (VAF) of at least 2% using our institution's next generation sequencing (NGS) panel (OncoHeme, Mayo Clinic)\n* ARM D: ECOG performance status (PS) 0, 1 or 2\n* ARM D: Patients must meet at least 1 of these 3 laboratory criteria to be enrolled:\n\n  * Hemoglobin =\\\u003C 10g\u002FdL (obtained =\\\u003C 7 days prior to registration)\n  * Absolute neutrophil count (ANC) =\\\u003C 1000\u002Fmm\\^3 (obtained =\\\u003C 7 days prior to registration)\n  * Platelet count =\\\u003C 100,000\u002Fmm\\^ 3 (obtained =\\\u003C 7 days prior to registration)\n* ARM D: Total bilirubin =\\\u003C 2 x ULN (if \\> 2 x ULN direct bilirubin is required and should be =\\\u003C 1.5 x ULN) (obtained =\\\u003C7 days prior to registration)\n* ARM D: Alanine aminotransferase (ALT) and aspartate transaminase (AST) =\\\u003C 3 x ULN (=\\\u003C 5 x ULN for patients with liver involvement) (obtained =\\\u003C7 days prior to registration)\n* ARM D: Creatinine =\\\u003C 1.6 mg\u002FdL (obtained =\\\u003C7 days prior to registration). If \\> 1.6, then the Calculated creatinine clearance must be \\>= 55 ml\u002Fmin using the Cockcroft-Gault formula\n* ARM D: Negative pregnancy test, for persons of childbearing potential only (obtained =\\\u003C 7 days prior to registration). NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* ARM D: Provide written informed consent\n* ARM D: Willingness to have a central venous line (PICC or PORT)\n* ARM D: Willingness to provide mandatory blood specimens for correlative research\n* ARM D: Willingness to return to enrolling institution (MCR) for follow-up (during the active monitoring phase of the study)\n* ARM D: Willingness to follow the requirements of the intravenous ascorbic acid program schedule\n* ARM E PRE-REGISTRATION: Age ≥ 18 years\n* ARM E PRE-REGISTRATION: New or an established diagnosis of 2016 World Health Organization (WHO) defined chronic myelomonocytic leukemia with a somatic TET2, IDH1, or IDH2 mutation requiring treatment with DNA methyltransferase inhibitors\u002Fhypomethylating agents\n* ARM E PRE-REGISTRATION: No prior CMML directed therapy.\n\n  * Exception: Received ≤ 1 cycle of azacitidine, decitabine, erythropoiesis stimulating agent therapy (ESA), or oral decitabine and cedazuridine. NOTE: Prior exposure to hydroxyurea is allowed. Continuation beyond the first cycle must be discussed with the principal investigator (PI)\n* ARM E PRE-REGISTRATION: Creatinine ≤ 1.6 mg\u002FdL. If \\> 1.6, then the Calculated creatinine clearance must be ≥ 55 ml\u002Fmin using the Cockcroft-Gault formula\n* ARM E PRE-REGISTRATION: Willingness to provide mandatory research bone marrow sample for correlative research\n* ARM E PRE-REGISTRATION: ECOG performance status (PS) 0, 1, or 2\n* ARM E PRE-REGISTRATION: Provide written informed consent\n* ARM E REGISTRATION: Willingness to provide mandatory blood specimens for correlative research\n* ARM E REGISTRATION: Willingness to return to enrolling institution (MCR) for follow-up (during the active monitoring phase of the study)\n* ARM E REGISTRATION: Recovered to grade 1 or baseline or established as sequelae from all toxic effects of previous therapy except alopecia\n* ARM E REGISTRATION: Absolute neutrophil count (ANC) ≥ 500\u002Fmm\\^3 (obtained ≤ 7 days prior to registration)\n* ARM E REGISTRATION: Platelet count ≥ 20,000\u002Fmm\\^3 (obtained ≤ 7 days prior to registration)\n* ARM E REGISTRATION: Total bilirubin ≤ 1.5 x ULN ( ≤ 3 x ULN for patients with Gilbert's syndrome) (obtained ≤ 7 days prior to registration)\n* ARM E REGISTRATION: Alanine aminotransferase (ALT) and aspartate transaminase (AST) ≤ 3 x ULN (obtained ≤ 7 days prior to registration)\n* ARM E REGISTRATION: Ability to complete questionnaire by themselves or with assistance\n* ARM E REGISTRATION: For a person of child-bearing potential (WOCBP): Must agree to use contraception or take measures to avoid pregnancy during the study. Adequate contraception is defined as follows:\n\n  * Complete true abstinence\n  * Consistent and correct use of one of the following methods of birth control:\n\n    * Male partner who is sterile prior to the female patient's entry into the study and is the sole sexual partner for that female patient\n    * Implants of levonorgestrel\n    * Injectable progestogen\n    * Intrauterine device (IUD) with a documented failure rate of less than 1% per year\n    * Oral contraceptive pill (either combined or progesterone only)\n    * Barrier method, for example: diaphragm with spermicide or condom with spermicide in combination with either implants of levonorgestrel or injectable progestogen\n* ARM E REGISTRATION: WOCBP must have a negative serum or urine pregnancy test ≤ 7 days prior to registration. NOTE: WOCBP include any person who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea \\> 12 consecutive months); or women on hormone replacement therapy with documented serum follicle stimulating hormone (FSH) level \\> 35 mIU\u002FmL. Even women who are using oral, implanted, or injectable contraceptive hormones or mechanical products such as an IUD or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), must be considered to be of child-bearing potential. NOTE: If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required\n* ARM E REGISTRATION: Persons who are able to father a child must use contraception during the study and for 3 months after the last treatment dose.\n\n  * Complete true abstinence\n  * Latex condom with a spermicidal agent\n  * Diaphragm with spermicide\n* ARM E REGISTRATION: Willingness to have a central venous line (PICC or PORT)\n* ARM E REGISTRATION: Willingness to follow the requirements of the intravenous ascorbic acid program schedule\n\nExclusion Criteria:\n\n* Any of the following:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential who are unwilling to employ adequate contraception\n* Any therapy =\\\u003C 2 weeks prior to registration; NOTE: Exception: patients on ibrutinib or corticosteroids (any dose) may continue therapy up until the new regimen has started at investigator discretion; corticosteroids can be tapered to lowest possible dose after start of treatment at investigator discretion. Exception: Palliative radiation is allowed\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pulmonary congestion or pulmonary edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* Receiving any other investigational agent which would be considered as a treatment for the lymphoma\n* Other active malignancy than lymphoma\n\n  * NOTE: If there is a history of prior malignancy, they must not be receiving other specific treatment for their cancer that could interfere with this protocol therapy; patients on hormonal therapy for treated breast or prostate cancer are permitted if they meet other eligibility criteria; patients with non-melanotic skin cancer may enroll\n* History of myocardial infarction =\\\u003C 6 months, or current symptomatic congestive heart failure or left ventricular ejection fraction (LVEF) \\\u003C 40% or with \\> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure\n* Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)\n* Patients with active central nervous system (CNS) lymphoma or active cerebrospinal fluid (CSF) involvement with malignant cells requiring CNS-specific therapy with IV or intrathecal (IT) methotrexate (MTX); Note: Patients with any prior CNS lymphoma (parenchymal or leptomeningeal) MUST be in complete remission (CR) in those compartments without any maintenance therapy required\n* Patients with uncontrolled or symptomatic kidney stones\n* Known paroxysmal nocturnal hemoglobinuria (PNH)\n* ARM D: Bona-fide hematological neoplasm\n* ARM D: Any of the following because this study involves an agent that has known genotoxic, mutagenic and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential who are unwilling to employ adequate contraception\n* ARM D: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* ARM D: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, pulmonary congestion or pulmonary edema, clinical dehydration, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* ARM D: History of myocardial infarction =\\\u003C 6 months, or current symptomatic congestive heart failure or known LVEF \\\u003C 40% or with \\> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure\n* ARM D: Patients with uncontrolled or symptomatic kidney stones\n* ARM D: Known paroxysmal nocturnal hemoglobinuria (PNH)\n* ARM D: Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)\n* ARM E PRE-REGISTRATION: Myelodysplastic syndrome (MDS)\u002Fmyeloproliferative neoplasm (MPN) overlap syndromes other than CMML\n* ARM E PRE-REGISTRATION: Active central nervous system disease\n* ARM E PRE-REGISTRATION: Any active disease condition that would render the protocol treatment dangerous or impair the ability of the patient to receive study drug\n* ARM E PRE-REGISTRATION: Concurrent active malignancy, except adequately treated nonmelanoma skin cancer. History of curatively treated in situ cancer of the cervix, curatively treated in situ cancer of the breast, or other solid tumors curatively treated is allowed as long as there is no evidence of disease for \\> 2 years\n* ARM E PRE-REGISTRATION: Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* ARM E PRE-REGISTRATION: Disease requiring systemic treatment with systemic immunosuppression with steroid steroids at a dose of ≥ 20 mg\u002Fday prednisone (or equivalent). Exceptions: Intermittent use of bronchodilators or inhaled steroids, local steroid injections, topical steroids\n* ARM E PRE-REGISTRATION: Patients with uncontrolled or symptomatic kidney stones\n* ARM E REGISTRATION: New York Heart Association (NYHA) class III\u002FIV heart failure or active angina\u002Fangina equivalents\n* ARM E REGISTRATION: History of myocardial infarction ≤ 6 months, or current symptomatic congestive heart failure or known LVEF \\\u003C 40% or with \\> grade 2 diastolic dysfunction, with no symptoms or signs of heart failure\n* ARM E REGISTRATION: Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, clinically significant cardiac arrhythmia, unstable angina pectoris, clinically significant nonhealing or healing wounds, pulmonary congestion or pulmonary edema, significant pulmonary disease (shortness of breath at rest or mild exertion), uncontrolled infection, clinical dehydration, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements\n* ARM E REGISTRATION: Known G6PD (glucose-6-phosphate dehydrogenase) deficiency (below lower limit of normal)\n* ARM E REGISTRATION: Any of the following because this study involves an agent that has known genotoxic, mutagenic, and teratogenic effects:\n\n  * Pregnant persons\n  * Nursing persons\n  * Persons of childbearing potential who are unwilling to employ adequate contraception",{"count":201,"type":20},80,[102],"This phase II trial studies the effect of ascorbic acid and combination chemotherapy in treating patients with lymphoma that has come back (recurrent) or does not respond to therapy (refractory), clonal cytopenia of undetermined significance and chronic myelomonocytic leukemia (CMML). Ascorbic acid may make cancer cells more sensitive to chemotherapy. Drugs used in chemotherapy, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ascorbic acid and combination chemotherapy may kill more cancer cells.\n\nArms A, B, C, and D are closed to enrollment.",[40,205,206,207,208,209,210,211],"High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements","Recurrent Diffuse Large B-Cell Lymphoma","Recurrent Hodgkin Lymphoma","Recurrent Lymphoma","Refractory Diffuse Large B-Cell Lymphoma","Refractory Lymphoma","Chronic Myelomonocytic Leukemia","2026-04-13",{"date":214,"type":54},"2026-04-16",{"date":216,"type":54},"2018-03-23",{"date":218,"type":20},"2033-11-02",{"name":220,"class":61},"Mayo Clinic",4,{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":227,"acronym":4,"eligibilityCriteria":228,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":229,"targetDuration":4,"studyType":100,"phases":231,"briefSummary":232,"conditions":233,"keywords":235,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":62},"100476367","phase-2-statins-in-patients-with-clonal-cytopenia-of-undetermined-significance-ccus-and-myelodysplastic-syndromes-mds-100476367","NCT05483010","Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)","Pilot Study of Statins in Patients With Clonal Cytopenia of Undetermined Significance (CCUS) and Myelodysplastic Syndromes (MDS)","Inclusion Criteria:\n\n* Diagnosis of CCUS or lower-risk MDS as defined below:\n\n  * CCUS is defined as the presence of somatic mutation(s) in recurrently mutated genes identified through the clinical MyeloSeq assay with a VAF ≥ 2% in the absence of bone marrow morphology\u002Fcytogenetic changes diagnostic of MDS PLUS unexplained persistent cytopenia in at least one lineage for at least 6 months:\n\n    * Hemoglobin \\\u003C 11.3 g\u002FdL in females or \\\u003C 13 g\u002FdL in males\n    * ANC \\\u003C 1.8 x 109\u002FL\n    * Platelets \\\u003C 150 x 109\u002FL\n  * MDS is defined using the WHO 2016 definition and classified into lower-risk if IPSS-R score is ≤ 3.5 . Lower-risk MDS will be required to have at least one mutation in a recurrent mutated gene with a VAF ≥ 2%.\n* Patient must be transfusion independent.\n* At least 18 years of age.\n* Ability to understand and willingness to sign an IRB approved written informed consent document (or that of legally authorized representative, if applicable).\n\nExclusion Criteria:\n\n* CCUS patients with cytogenetic change alone.\n* Current or prior use of disease-modifying therapy (e.g., lenalidomide, Luspatercept, Imitelstat, HMAs, venetoclax) with any dose within the last 3 months, with the exception of concurrent use of erythropoetin stimulating agents\n* Prior use of a statin within 1 year prior to start of treatment.\n* A history of other malignancy with the exception of malignancies for which all treatment was completed at least 2 years before registration and the patient has no evidence active of disease.\n* Currently receiving any investigational agent for CCUS\u002FMDS. The minimum interval between the last dose of investigational agent used for CCUS\u002FMDS and Day 1 of this trial should be 5 half-lives of the investigational agent.\n* A history of allergic reactions or intolerance attributed to compounds of similar chemical or biologic composition to atorvastatin, rosuvastatin, any other statin, or other agents used in the study.\n* Uncontrolled intercurrent illness including, but not limited to, symptomatic infection, sepsis, or active liver disease (acute liver failure, decompensated cirrhosis, or persistent elevation in ALT or AST \\> 3 x ULN), or any other comorbidity that would preclude statin use based on FDA recommendation.\n* Pregnant and\u002For breastfeeding. Women of childbearing potential must have a negative pregnancy test within 14 days of study entry.\n* Patients with HIV and HCV are not eligible for the trial if they are concomitantly receiving active treatment for HIV\u002FHCV given the concern for potential drug interactions. The minimum interval between the last dose of antiviral and enrollment into the study should be 28 days or 5 half-lives of the antiviral drug, whichever is longer. The liver function profile of eligible HIV\u002FHCV patients must be within the acceptable limits.",{"count":230,"type":20},16,[102],"Patients with clonal cytopenia of undetermined significance (CCUS) and lower-risk myelodysplastic syndromes (MDS) have a life expectancy of 5 to 10 years. Mortality in these patients results from progression of disease to higher-risk MDS or acute myeloid leukemia (AML) and cardiovascular events. Currently there are no FDA-approved treatments with the potential to improve survival of patients with CCUS and lower-risk MDS. Statins are an appealing class of drugs to consider in this situation as preclinical data support their potential to suppress progression of myeloid malignancy, and they have a well-established role in prevention of major cardiovascular events. This is a pilot study to explore the role of statins in treatment of patients with CCUS and lower-risk MDS. In this study, change in inflammatory biomarkers and variant allele frequency (VAF) of somatic mutations will be used as a surrogate marker of response to statin therapy. The hypothesis is that the use of statins at diagnosis of CCUS or lower-risk MDS will reduce inflammation and delay or prevent the expected increase in the VAF of somatic mutations over time.",[40,234],"Myelodysplastic Syndromes",[48,236,237,238],"MDS","Statins","Inflammation","2026-04-02",{"date":241,"type":54},"2026-04-08",{"date":243,"type":54},"2024-02-19",{"date":245,"type":20},"2027-05-31",{"name":140,"class":61},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":252,"acronym":4,"eligibilityCriteria":253,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":254,"targetDuration":4,"studyType":100,"phases":256,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":262,"lastUpdatePostDateStruct":263,"startDateStruct":265,"completionDateStruct":267,"leadSponsor":269,"locationsCount":271},"100520970","phase-2-curcumin-to-improve-inflammation-and-symptoms-in-patients-with-clonal-cytopenia-of-undetermined-significance-low-risk-myelodysplastic-syndrome-and-myeloproliferative-neoplasms-100520970","NCT06063486","Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms","A Phase 2, Double-blind, Randomized Study to Compare the Effect of Curcumin Versus Placebo on Inflammatory Cytokines, Symptoms and Disease Parameters in Clonal Cytopenia of Undetermined Significance (CCUS), Low-Risk Myelodysplastic Syndrome (LR-MDS), and Myeloproliferative Neoplasms (MPNs)","Inclusion Criteria:\n\n* Age \\>= 18\n* Eastern Cooperative Oncology Group (ECOG) =\\\u003C 2\n* Ability to understand and willingness to sign a written informed consent\n* Diagnosis of polycythemia vera (PV), essential thrombocytosis (ET) or myelofibrosis (MF) per World Health Organization (WHO) 2016 diagnostic criteria\n\n  * Presence of at least one symptom measurable using the MPN-\u002FSymptom Assessment Form (SAF) with a severity greater than 3\n  * MPN patients determined to have stable disease undergoing surveillance and unlikely to require initiation of new cytoreductive therapy (i.e., hydroxyurea, ruxotinib, interferon within the study period); patients on a stable dose of hydroxyurea for at least 6 months who meet the other inclusion\u002Fexclusion criteria may be included\n* A diagnosis of CCUS or LR-MDS\n\n  * CCUS defined as persistent cytopenia for \\> 6 months (hemoglobin \\[Hgb\\] \\\u003C 11.3 g\u002FdL \\[7 mmol\u002FL\\] in women and Hgb \\\u003C 12.9 g\u002FdL \\[8 mmol\u002FL\\] in men, platelet \\\u003C 150 x 10\\^9\u002FL or neutrophils \\\u003C 1.8 x 10\\^9\u002FL), normal cytogenetics, presence of detectable MDS associated mutations and bone marrow morphology non-diagnostic of MDS or any other malignancies\n  * LR-MDS as defined by WHO 2016 diagnosis criteria\n  * Minimum baseline symptom score of 25 in the fatigue section of the symptom questionnaire\n\nExclusion Criteria:\n\n* Patients with intake of curcumin as a dietary supplement, including multivitamin and unwillingness to quit more than 24 hours before study start\n* Patients with inability to understand and adhere to information given\n* Patients receiving active treatment for another malignancy except with hormonal therapy for a malignancy considered to be in remission or growth factors (erythropoietin, granulocyte colony-stimulating factor \\[G-CSF\\] and luspatercept)\n* Patients with intermediate or high-risk MDS\n* Patients must not be pregnant or nursing\n* Patients must not be on any oral or intravenous steroid or any other anti-inflammatories (ibuprofen \\> 200mg\u002Fweek or 400mg\u002Fmonth, naproxen of any dose, \\> 325mg aspirin daily, any herbal anti-inflammatory concoction of any dose)",{"count":255,"type":20},30,[102],"This phase II trial evaluates how a curcumin supplement (C3 complex\u002FBioperine) changes the inflammatory response and symptomatology in patients with clonal cytopenia of undetermined significance (CCUS), low risk myelodysplastic syndrome (LR-MDS), and myeloproliferative neoplasms (MPN). Chronic inflammation drives disease development and contributes to symptoms experienced by patients with CCUS, LR-MDS, and MPN. Curcumin has been shown to have anti-inflammatory and anti-cancer properties and has been studied in various chronic illnesses and hematologic diseases.",[40,259,78,260,261],"Essential Thrombocythemia","Myelofibrosis","Polycythemia Vera","2026-03-24",{"date":264,"type":54},"2026-03-27",{"date":266,"type":54},"2024-03-01",{"date":268,"type":20},"2027-03-01",{"name":270,"class":61},"University of Southern California",2,{"id":273,"slug":274,"hasResults":11,"nctId":275,"briefTitle":276,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":278,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":279,"targetDuration":4,"studyType":100,"phases":280,"briefSummary":281,"conditions":282,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":62},"100559639","phase-2-a-phase-2-study-evaluating-olutasidenib-in-patients-with-idh1-mutated-clonal-cytopenia-of-undetermined-significance-and-lower-risk-myelodysplasticsyndromeschronic-myelomonocytic-leukemia-100559639","NCT06566742","A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic\u002FSyndromes\u002FChronic Myelomonocytic Leukemia.","Inclusion Criteria:\n\n1. Pathologically proven CCUS or lower-risk MDS\u002FCMML.\n\n   1. CCUS is defined as the presence of cytopenia (absolute neutrophil count \\\u003C 1.8 x 10\\^9\u002FL, hemoglobin \\\u003C 13 g\u002FdL in males or \\\u003C 12 g\u002FdL in females, and\u002For platelets \\\u003C 150 x 10\\^9\u002FL) for at least 30 days that are otherwise unexplained and with no diagnostic hematopathologic features of myeloid neoplasms. Patients with known Duffy-null phenotype must have absolute neutrophil counts less than their lower limit of normal.\n   2. Lower-risk MDS\u002FCMML includes patients with International Prognostic Scoring System (IPSS) low- or intermediate-1-risk disease and Revised IPSS (IPSS-R) score ≤ 3.5 and Molecular IPSS (IPSS-M) very low-, low-, or moderate low-risk categories.\n2. Patients must have a documented IDH1 mutation with variant allele frequency (VAF) ≥ 0.02.\n3. Patients ≥ 18 years old.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2\n5. Bilirubin ≤ 2 times upper limit of normal (ULN) or ≤ 3 times ULN in patients with Gilbert Syndrome.\n6. Aspartate transaminase (AST), alanine transaminase (ALT), and alkaline phosphatase ≤ 3 times ULN.\n7. Acceptable renal function with serum creatinine ≤ 1.5 times ULN or calculated creatinine clearance ≥ 50 mL\u002Fmin (as assessed by Cockcroft-Gault, Modification of Diet in Renal Disease Formula \\[MDRD\\], or Chronic Kidney Disease Epidemiology \\[CKD-Epi\\] validated measures).\n8. Negative serum or urine pregnancy test if female of childbearing potential.\n9. For fertile men and women, agreement to use highly effective contraceptive methods for the duration of study participation and 90 days after the last dose of study medication. Appropriate highly effective method(s) of contraception include oral or injectable hormonal birth control, intrauterine device (IUD), and double barrier methods (for example a condom in combination with a spermicide).\n10. Agreement for male patients not to donate sperm and for female patients of childbearing potential not to donate ova during the study and for 90 days after the final dose of study drug.\n11. Ability and willingness to signed informed consent prior to beginning study and undergoing procedures.\n\nExclusion Criteria:\n\n1. Patients unable to swallow oral medications, or patients with gastrointestinal conditions (e.g., malabsorption, resection, etc.) deemed by the Investigator to jeopardize intestinal absorption.\n2. Patients with any concurrent uncontrolled clinically significant medical condition, including life-threatening severe infection or psychiatric illness, which could place the patient at unacceptable risk of study treatment.\n3. Known active hepatitis B (hepatitis B virus \\[HBV\\]) or hepatitis C (hepatitis C virus \\[HCV\\]) or HIV infection.\n4. Pregnant or nursing women or women of childbearing potential not using highly effective contraception; male patients not using highly effective contraception as defined in the inclusion criteria.\n5. Subject with white blood cell count \\> 25 x10\\^9\u002FL.\n\n   * Note: hydroxyurea use is permitted to meet this criterion with no washout required.\n6. Unwillingness or inability to comply with procedures either required in this protocol or considered standard of care.",true,{"count":124,"type":20},[102],"To learn if olutasidenib can help to control CCUS, MDS, and\u002For CMML. The safety of the drug will also be studied.",[234,211,40],"2026-03-02",{"date":285,"type":54},"2026-03-04",{"date":287,"type":54},"2024-12-10",{"date":289,"type":20},"2029-08-31",{"name":291,"class":61},"M.D. Anderson Cancer Center",{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":100,"phases":299,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":312,"lastUpdatePostDateStruct":313,"startDateStruct":315,"completionDateStruct":317,"leadSponsor":319,"locationsCount":320},"100282586","pre-myeloid-cancer-and-bone-marrow-failure-clinic-study-100282586","NCT02958462","Pre-myeloid Cancer and Bone Marrow Failure Clinic Study","Inclusion Criteria:\n\n* Patients with idiopathic cytopenias of unclear significance (ICUS)\n* Patients with clonal hematopoiesis of indeterminate significance (clonal hematopoiesis of indeterminate potential \\[CHIP\\]), including the recently described CHIP syndrome called VEXAS (vacuoles, E1 ubiquitin ligase, X chromosomal, autoimmune and somatic)\n* Patients with clonal cytopenias of undetermined significance (CCUS)\n* Marrow failure syndromes with myeloid malignancy predisposition - telomere dysfunction, chromosomal breakage disorders\n* Germ line inherited syndromes with risk for malignant transformation - GATA2, CEBPA, ETV-6, RUNX1, JAK2, PF6, etc.\n* Low risk MDS (idiopathic dysplasia of unclear significance)\n* Family member of a patient with one of the above conditions\n* Patient at high risk or suspected of developing one of the above conditions\n\nExclusion Criteria:\n\n* Patients under 18 years of age",{"count":172,"type":20},[300],"NA","This clinical trial tests next generation sequencing (NGS) for the detection of precursor features of pre-myeloid cancers and bone marrow failure syndromes. NGS is a procedure that looks at relevant cancer associated genes and what they do. Finding genetic markers for pre-malignant conditions may help identify patients who are at risk of pre-myeloid cancers and bone marrow failure syndromes and lead to earlier intervention.",[303,304,305,77,306,40,75,307,308,309,180,310,311],"Myeloid Malignancy","Inherited Bone Marrow Failure Syndrome","Clonal Expansion","Bone Marrow Failure Syndrome","Hematologic Neoplasms","Hematopoietic and Lymphatic System Neoplasm","Hereditary Neoplastic Syndrome","Idiopathic Dysplasia of Uncertain Significance","Low Risk Myelodysplastic Syndrome","2026-02-20",{"date":314,"type":54},"2026-02-23",{"date":316,"type":54},"2017-01-16",{"date":318,"type":20},"2035-09-15",{"name":220,"class":61},3,{"id":322,"slug":323,"hasResults":11,"nctId":324,"briefTitle":325,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":100,"phases":330,"briefSummary":331,"conditions":332,"keywords":4,"overallStatus":50,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":342},"100488570","phase-2-canakinumab-for-the-prevention-of-progression-to-cancer-in-patients-with-clonal-cytopenias-of-unknown-significance-impact-study-100488570","NCT05641831","Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study","A Randomized Double-Blind Placebo-Controlled Phase II Multi-Center Study of Inflammation Modification of Canakinumab to Prevent Leukemic Progression of Clonal Cytopenias of Unknown Significance (CCUS): IMPACT Study","Inclusion Criteria:\n\n* Patients with age \\>= 18 with high-risk CCUS\n* Must meet ALL the following criteria:\n\n  * Unexplained, clinically meaningful cytopenias (greater than 4 months) in one or more of the following lineages: erythroid cells, neutrophils, platelets. Clinically meaningful cytopenia is institution specific and threshold may vary on age, sex, and race. Decision-making should depend upon lab values specific to the institution and supersede public works. Based upon published work, significant cytopenias are defined as the following (must meet criteria in at least one lineage):\n\n    * Erythroid Cells:\n\n      * Hemoglobin \\\u003C 11 g\u002FdL\n    * White Blood Cells:\n\n      * Absolute Neutrophil Count \\\u003C 1800\u002FmicroL and \\> 500\u002FmicroL\n    * Platelets:\n\n      * Platelet Count \\\u003C 150,000\u002FmicroL and \\> 50,000\u002FmicroL\n  * MDS criteria not fulfilled\n  * No other evidence of hematological malignancy\n  * No or only mild (\\\u003C 10%) bone marrow dysplasia\n  * Blast cells \\\u003C 5% detected via morphologic examination of blood and\u002For bone marrow smears which can also be supported by flow cytometry and\u002For immunohistochemical studies\n  * Any of the following:\n\n    * Isolated somatic spliceosome mutation at any VAF (SRSF2, SF3B1, U2AF1, or ZRSR2)\n    * Isolated TP53 mutation greater than 5% VAF\n    * At least 1 mutation in TET2, DMNT3A, or ASXL1 at any VAF coupled with at least 1 other known myeloid pathogenic somatic mutation or known pathogenic germline mutation that predisposes to myeloid malignancy as determined by next generation sequencing and bone marrow biopsy\n    * A TET2, DMNT3A, or ASXL1 greater than 10% VAF coupled with another TET2, DMNT3A, or ASXL1 greater than 10% VAF\n    * The presence of two or more known myeloid pathogenic somatic or germline mutations (other than TET2, ASXL1, DMNT3A, TP53, or spliceosome mutations) greater than 10% VAF\n* Ability to understand and willingness to sign the written informed consent document\n* Eastern Cooperative Oncology Group (ECOG) performance status 0, 1, or 2\n* Patients with a history of hypertension or active hypertension are strongly encouraged to optimize blood pressure control\n* Creatinine clearance greater than 45 ml\u002Fmin using Cockcroft-Gault\n* Total bilirubin =\\\u003C 1.5 x ULN\n* Aspartate transaminase (AST) \\\u003C 3 x ULN\n* Alanine transaminase (ALT) \\\u003C 3 x ULN\n\nExclusion Criteria:\n\n* Concurrent malignancy requiring active systemic therapy\n* Diagnosis of MDS or any other myeloid malignancy in the patient's lifetime\n* History of Hypersensitivity to canakinumab or drug of a similar class\n* Active infection requiring prompt evaluation and treatment or history of recurrent infections\n* Known active or recurrent hepatic disorder including cirrhosis, hepatitis B and C (via positive or indeterminate central laboratory \\[lab\\] results)\n* Subjects with active tuberculosis. In subjects with a history of tuberculosis but without active tuberculosis, if the results of the evaluation require treatment per local guidelines, then the treatment should be initiated before randomization (unless otherwise required by Health Authorities or Institutional Review Board (IRB) in which case curative treatment must be completed prior to screening)\n* Subjects with suspected or proven immunocompromised state or infections. If the results of this screening per local treatment guidelines or clinical practice require treatment for said infection then the patient is not eligible. Suspected or proven immunocompromised states or infections include:\n\n  * Those with any other medical condition such as active infection, treated or untreated, which in the opinion of the investigator places the subject at an unacceptable risk for participation in immunomodulatory therapy. If in the opinion of the investigator, the patient's immunocompromised state does not pose an unacceptable risk for participation, in the absence of uncontrolled infection, and the patient does not have a history of serious infections (such as tuberculosis); then the patient may participate in this study.\n  * Known history of testing positive for human immunodeficiency virus (HIV) infections. For countries where HIV status is mandatory: testing positive for HIV during screening using a local test.\n  * Allogeneic bone marrow or solid organ transplant (history of any or within a certain period of time?)\n  * Those requiring systemic or local treatment in doses with systemic effects e.g.:\n\n    * Prednisone \\> 20 mg (or equivalent) oral or intravenous daily for \\> 14 days\n    * Prednisone \\> 5 mg and =\\\u003C 20 mg (or equivalent) daily for \\> 30 days\n    * Equivalent dose of methotrexate \\> 15 mg weekly\n    * Note: Azathioprine is allowed. Daily glucocorticoid-replacement for conditions such as adrenal or pituitary insufficiency is allowed. Topical, inhaled or local steroid use in doses that are not considered to cause systemic effects are permitted. Steroids for pre-medication related to chemotherapy as per local standard of care are permitted.\n* Live or attenuated vaccination within 3 months prior to first dose of study drug (e.g. Measles\u002FMumps\u002FRubella \\[MMR\\], Yellow Fever, Rotavirus, Smallpox, etc.) and after initiation of canakinumab treatment\n* Use of erythropoietin stimulating agents (ESA) or growth factors within four weeks prior to the start of the study\n* Pregnant or nursing women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive human chorionic gonadotropin (hCG) laboratory test. Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using basic methods of contraception during dosing of study treatment and for up to 130 days after last dose of study drug. Basic contraception methods include:\n\n  * Total abstinence (when this is in line with the preferred and usual lifestyle of the subject. Periodic abstinence (e.g., calendar, ovulation, symptothermal, post-ovulation methods) and withdrawal are not acceptable methods of contraception\n  * Female sterilization (have had surgical bilateral oophorectomy with or without hysterectomy), total hysterectomy or bilateral tubal ligation at least 6 weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment\n  * Male sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject\n  * Barrier methods of contraception: Condom or Occlusive cap (diaphragm or cervical\u002Fvault caps). For UK: with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002F vaginal suppository\n  * Use of oral, injected or implanted hormonal methods of contraception or other forms of hormonal contraception that have comparable efficacy (failure rate \\\u003C 1%), for example hormone vaginal ring or transdermal hormone contraception or placement of an intrauterine device (IUD) or intrauterine system (IUS). In case of use of oral contraception women should have been stable on the same pill for a minimum of 3 months before taking study treatment. Prior to entry into this study, cisplatin-based chemotherapy, which may be toxic to the fetus, may be given. The time between the end of cisplatin-based chemotherapy and the start canakinumab\u002Fplacebo treatment is variable, resulting in a variable need for continuation of highly effective contraception. Women are considered post-menopausal and not of child bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (i.e. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy), total hysterectomy, or bilateral tubal ligation at least six weeks prior to first dose of study drug. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential. If local regulations deviate from the contraception methods listed above to prevent pregnancy, local regulations apply and will be described in the Informed Consent Form (ICF).",{"count":329,"type":20},110,[102],"This phase II trial tests how well canakinumab works to prevent progression to cancer in patients with clonal cytopenias of unknown significance (CCUS). CCUS is a blood condition defined by a decrease in blood cells. Blood cells are composed of either red blood cells, white blood cells, or platelets. In patients with CCUS, blood counts have been low for a long period of time. Patients with CCUS also have a mutation in one of the genes that are responsible for helping blood cells develop. The combination of genetic mutations and low blood cell counts puts patients with CCUS at a higher risk to develop blood cancers in the future. This transformation from low blood cell counts to cancer may be caused by inflammation in the body. Canakinumab is a monoclonal antibody that may block inflammation in the body by targeting a specific antibody called the anti-human interleukin-1beta (IL-1beta).",[40],"2025-12-31",{"date":335,"type":54},"2026-01-02",{"date":337,"type":54},"2023-02-06",{"date":339,"type":20},"2028-12-31",{"name":341,"class":61},"Uma Borate",6]